Ziconotide for treatment of severe chronic pain
@article{Schmidtko2010ZiconotideFT, title={Ziconotide for treatment of severe chronic pain}, author={Achim Schmidtko and J{\"o}rn L{\"o}tsch and Rainer Freynhagen and Gerd Geisslinger}, journal={The Lancet}, year={2010}, volume={375}, pages={1569-1577} }
271 Citations
Intrathecal Ziconotide: A Review of Its Use in Patients with Chronic Pain Refractory to Other Systemic or Intrathecal Analgesics
- MedicineCNS Drugs
- 2013
Intrathecal ziconotide provides a treatment option for patients with severe, unremitting pain who have failed to respond to other intensive analgesic regimens and for enhancing its efficacy and tolerability.
Ziconotide: a clinical update and pharmacologic review
- Medicine, BiologyExpert opinion on pharmacotherapy
- 2013
Ziconotide is a safe and effective strategy to treat chronic pain, although limitations remain, including a small therapeutic window, and low starting doses and slow incremental increases and long titration intervals may improve tolerability.
Intrathecal Administration of Ziconotide as a Potential Treatment for Chronic Migraines
- MedicineCureus
- 2022
Ziconotide is proposed to have efficacy for chronic neuropathic pain, with a favorable lack of tolerance and chemical dependency, and is reported to have use for chronic refractory migraines.
Intracerebroventricular Pain Treatment with Analgesic Mixtures including Ziconotide for Intractable Pain.
- MedicinePain physician
- 2016
Using ziconotide by intracerebroventricular infusion seems safe and efficient, specifically for chronic neoplastic pain of cervicocephalic, thoracic, or diffuse origin and also for pain arising from a central neuropathic mechanism.
Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain
- Biology, MedicineNature Reviews Neurology
- 2014
The failure of previously tested antioxidants, neuroprotective agents, anticonvulsants and antidepressants as therapeutic or preventative strategies are discussed, and individualized, mechanism-based therapeutic options for CIPNP associated with each of the three main drug groups are suggested.
Pharmacogenetics of chronic pain management.
- Medicine, BiologyClinical biochemistry
- 2014
Intrathecal combination of ziconotide and morphine for refractory cancer pain: A rapidly acting and effective choice
- MedicinePAIN
- 2012
Omega-Conotoxins as Experimental Tools and Therapeutics in Pain Management
- Biology, MedicineMarine drugs
- 2013
There remains a critical need to improve the convenience of peptide drug delivery methods, and reduce the number and severity of adverse effects associated with ω-conotoxin-based therapies, in the treatment of neuropathic pain.
Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials
- MedicineCurrent neuropharmacology
- 2017
The results suggest that ziconotide is beneficial for pain reduction in chronic neuropathic pain, however, there remain some methodological issues that may call into question the validity of the results.
Intrathecal Ziconotide and Morphine for Pain Relief: A Case Series of Eight Patients with Refractory Cancer Pain, Including Five Cases of Neuropathic Pain
- MedicineNeurology and Therapy
- 2015
Adding ziconotide to intrathecal opioid-based therapy in cancer patients with neuropathic pain inadequately controlled by intratheCal morphine alone is recommended on the basis of clinical experience.
References
SHOWING 1-10 OF 74 REFERENCES
Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.
- Biology, MedicineInternational journal of clinical pharmacology and therapeutics
- 2006
Ziconotide is a new and valuable alternative analgesic for the acute and long-term treatment of severe pain, especially in patients refractory to opioids.
Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain
- Medicine, BiologyExpert review of neurotherapeutics
- 2006
Ziconotide is a new nonopioid intrathecal agent recently approved for the treatment of chronic pain that blocks the N-type calcium channels located in the superficial dorsal horn of the spinal cord, resulting in potent analgesia.
Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
- Biology, Medicine
- 2004
Ziconotide provides significant pain relief to severe chronic pain sufferers who have failed to obtain relief from opiate therapy and no evidence of tolerance to ziconotide is seen in these patients, and is likely to be the first in a new class of neurological drugs: the N-type calcium channel blockers, or NCCBs.
Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
- Biology, MedicineCurrent medicinal chemistry
- 2004
Ziconotide is a neuroactive peptide in the final stages of clinical development as a novel non-opioid treatment for severe chronic pain and will be the first in a new class of neurological drugs: the N-type calcium channel blockers, or NCCBs.
Ziconotide: an update and review.
- MedicineExpert opinion on pharmacotherapy
- 2008
Ziconotide is a synthetic neuroactive peptide equivalent to the omega conotoxin MVIIA, a constituent of the venom of the fish-hunting marine snail Conus magus, and has a steep dose-response curve, a slow onset of action and a narrow margin of safety and responses to dose adjustments are slow.
Ziconotide, an Intrathecally Administered N‐Type Calcium Channel Antagonist for the Treatment of Chronic Pain
- Medicine, BiologyPharmacotherapy
- 2005
In early clinical trials, frequent and severe psychiatric and central nervous system adverse effects were associated with rapid intrathecal infusion and frequent up‐titration, and patients with psychiatric symptoms are not candidates for this drug.
An effective treatment of severe complex regional pain syndrome type 1 in a child using high doses of intrathecal ziconotide.
- MedicineJournal of pain and symptom management
- 2006
Treatment challenges and complications with ziconotide monotherapy in established pump patients.
- Medicine, PsychologyPain physician
- 2006
Achieving adequate analgesia, reducing Ziconotide to mitigate adverse physiological effects, managing opioid withdrawal symptoms, and supportive psychological consultation were combined to achieve successful outcomes in two of three patients.
Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain
- BiologyTherapeutics and clinical risk management
- 2009
Ziconotide is a conopeptide intrathecal analgesic which provides analgesia via binding to N-type voltage-sensitive calcium channels in the spinal cord and is approved by the US FDA for the management of severe chronic pain.
Formulary Forum: Intrathecal Ziconotide for Refractory Chronic Pain
- Medicine, BiologyThe Annals of pharmacotherapy
- 2006
Ziconotide is a therapeutic option for treatment of severe chronic pain in patients who have exhausted all other agents, including intrathecal morphine, and for whom the potential benefit outweighs the risks of serious neuropsychiatric adverse effects and of having an implanted device.